Analgesic efficacy of sacral neuromodulation for chronic pelvic cancer pain
Background: Neuromodulation has provided promising results in chronic pain management. Sacral neurostimulation (SNS) is a neuromodulatory technique, where the sacral nerve roots are electrically stimulated. Objective: Evaluate the efficacy of the trial phase to control severe cancer pain in pelvic o...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-10-01
|
| Series: | Saudi Journal of Anaesthesia |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/sja.sja_307_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846173800433975296 |
|---|---|
| author | Khaled M. Fares Sahar A. B. Mohamed Diab F. Hetta Moaaz Mohamed Tohamy Nourhan A. Elgalaly Nayira M. Elhusseini Fatma Adel El Sherif |
| author_facet | Khaled M. Fares Sahar A. B. Mohamed Diab F. Hetta Moaaz Mohamed Tohamy Nourhan A. Elgalaly Nayira M. Elhusseini Fatma Adel El Sherif |
| author_sort | Khaled M. Fares |
| collection | DOAJ |
| description | Background:
Neuromodulation has provided promising results in chronic pain management. Sacral neurostimulation (SNS) is a neuromodulatory technique, where the sacral nerve roots are electrically stimulated.
Objective:
Evaluate the efficacy of the trial phase to control severe cancer pain in pelvic organs.
Design:
Pilot study.
Methods:
Chronic pelvic cancer pain patients were managed with morphine ≥ 60 mg daily, duloxetine 30 mg, and celecoxib 200 mg twice daily. Twenty-two adults were divided randomly into two equal groups: the SNS group (N = 11), received a sacral neurostimulator device and opioid analgesics, and the opioid group (N = 11), received increased opioid analgesics to control pain.
Results:
Visual analog scale scores were decreased in the SNS group at 24 h, 4 days, 1, and 2 weeks in SNS compared to the opioid group, medians (IQR) [4 (3–5) vs 6 (5–7), 3 (3–4) vs 5 (5–6), 3 (3–4) vs 5 (5–6), and 3 (3–3) vs 5 (4–6) P < 0.001], daily morphine consumption was reduced in the SNS group compared to the opioid group, median (IQR) [90 (60–90) mg vs 120 (120–150) mg, P < 0.001] and [30 (30–60) mg vs 150 (120–180) mg] during the first and second weeks. The SNS group had a better life quality compared to the opioid group after 2 weeks, median (IQR) was (123 (122.5–124) vs 117 (117–118.5) P < 0.001), respectively.
Conclusion:
The SNS trial device showed effectiveness in managing severe chronic pelvic cancer pain. |
| format | Article |
| id | doaj-art-18bc78d75c484cf3ae8b0253ca2223f6 |
| institution | Kabale University |
| issn | 1658-354X 0975-3125 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Saudi Journal of Anaesthesia |
| spelling | doaj-art-18bc78d75c484cf3ae8b0253ca2223f62024-11-08T10:54:31ZengWolters Kluwer Medknow PublicationsSaudi Journal of Anaesthesia1658-354X0975-31252024-10-0118453453910.4103/sja.sja_307_24Analgesic efficacy of sacral neuromodulation for chronic pelvic cancer painKhaled M. FaresSahar A. B. MohamedDiab F. HettaMoaaz Mohamed TohamyNourhan A. ElgalalyNayira M. ElhusseiniFatma Adel El SherifBackground: Neuromodulation has provided promising results in chronic pain management. Sacral neurostimulation (SNS) is a neuromodulatory technique, where the sacral nerve roots are electrically stimulated. Objective: Evaluate the efficacy of the trial phase to control severe cancer pain in pelvic organs. Design: Pilot study. Methods: Chronic pelvic cancer pain patients were managed with morphine ≥ 60 mg daily, duloxetine 30 mg, and celecoxib 200 mg twice daily. Twenty-two adults were divided randomly into two equal groups: the SNS group (N = 11), received a sacral neurostimulator device and opioid analgesics, and the opioid group (N = 11), received increased opioid analgesics to control pain. Results: Visual analog scale scores were decreased in the SNS group at 24 h, 4 days, 1, and 2 weeks in SNS compared to the opioid group, medians (IQR) [4 (3–5) vs 6 (5–7), 3 (3–4) vs 5 (5–6), 3 (3–4) vs 5 (5–6), and 3 (3–3) vs 5 (4–6) P < 0.001], daily morphine consumption was reduced in the SNS group compared to the opioid group, median (IQR) [90 (60–90) mg vs 120 (120–150) mg, P < 0.001] and [30 (30–60) mg vs 150 (120–180) mg] during the first and second weeks. The SNS group had a better life quality compared to the opioid group after 2 weeks, median (IQR) was (123 (122.5–124) vs 117 (117–118.5) P < 0.001), respectively. Conclusion: The SNS trial device showed effectiveness in managing severe chronic pelvic cancer pain.https://journals.lww.com/10.4103/sja.sja_307_24chronic painpelvic cancer painperineal cancer painsacral neuromodulatorsacral neuro-stimulator |
| spellingShingle | Khaled M. Fares Sahar A. B. Mohamed Diab F. Hetta Moaaz Mohamed Tohamy Nourhan A. Elgalaly Nayira M. Elhusseini Fatma Adel El Sherif Analgesic efficacy of sacral neuromodulation for chronic pelvic cancer pain Saudi Journal of Anaesthesia chronic pain pelvic cancer pain perineal cancer pain sacral neuromodulator sacral neuro-stimulator |
| title | Analgesic efficacy of sacral neuromodulation for chronic pelvic cancer pain |
| title_full | Analgesic efficacy of sacral neuromodulation for chronic pelvic cancer pain |
| title_fullStr | Analgesic efficacy of sacral neuromodulation for chronic pelvic cancer pain |
| title_full_unstemmed | Analgesic efficacy of sacral neuromodulation for chronic pelvic cancer pain |
| title_short | Analgesic efficacy of sacral neuromodulation for chronic pelvic cancer pain |
| title_sort | analgesic efficacy of sacral neuromodulation for chronic pelvic cancer pain |
| topic | chronic pain pelvic cancer pain perineal cancer pain sacral neuromodulator sacral neuro-stimulator |
| url | https://journals.lww.com/10.4103/sja.sja_307_24 |
| work_keys_str_mv | AT khaledmfares analgesicefficacyofsacralneuromodulationforchronicpelviccancerpain AT saharabmohamed analgesicefficacyofsacralneuromodulationforchronicpelviccancerpain AT diabfhetta analgesicefficacyofsacralneuromodulationforchronicpelviccancerpain AT moaazmohamedtohamy analgesicefficacyofsacralneuromodulationforchronicpelviccancerpain AT nourhanaelgalaly analgesicefficacyofsacralneuromodulationforchronicpelviccancerpain AT nayiramelhusseini analgesicefficacyofsacralneuromodulationforchronicpelviccancerpain AT fatmaadelelsherif analgesicefficacyofsacralneuromodulationforchronicpelviccancerpain |